HC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Addex Therapeutics (NASDAQ:ADXN) and maintained a price target of $30, indicating confidence in the company's future performance.
August 28, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Addex Therapeutics and maintained a $30 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $30 price target by HC Wainwright & Co. indicates strong confidence in Addex Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100